Clinical trials: Single Women
Bladder Cancer
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus…
- Trial name
- NCT00461591
- Testing
- Apaziquone, TURBT
- Where
- 74 sites in United States
- Volunteers
- 802 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Menopause, Healthy
Investigation of 2 Different Oral Formulations of Estradiol and Norethisterone in Healthy Women
This trial is conducted in Europe. The aim of this trial is to investigate whether a reformulated estradiol/norethisterone acetate (NETA) formulation is bioequivalent to that of Kliogest® (estradiol/norethisterone acetate (NETA)…
- Trial name
- NCT01596010
- Testing
- 2 mg estradiol / 1 mg norethisterone acetate (NETA)
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Menopause
Study Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation
The purpose of this trial is to determine the equivalence of 3 new formulations of a Premarin®/medroxyprogesterone acetate (MPA) combination tablet to the currently marketed dosage form (Prempro® [TM]).
- Trial name
- NCT00630435
- Testing
- Premarin®/MPA formulation A, Premarin®/MPA formulation B, Premarin®/MPA formulation C
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alopecia
Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
Phase II clinical trial
- Trial name
- ELAN (NCT02919735)
- Testing
- CG 428 cutaneous solution
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Legacy Healthcare SA
Renal Impairment
Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment
The purpose of this study is to characterize the effect of renal function on the PK of a 0.25 mg single oral dose of bevenopran in humans and to assess the safety and tolerability of bevenopran in patients with varying degrees of…
- Trial name
- NCT02508740
- Testing
- bevenopran
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Renal Impairment
Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419
The study is a two-center, Phase 1, open-label, single-dose, one-period, four groups, PK study in subjects with various severities of renal impairment and matched healthy controls.
- Trial name
- NCT05412472
- Testing
- GC4419
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Galera Therapeutics, Inc.
Invasive Group B Streptococcus (GBS) Disease
A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age
The goals of the proposed study are to evaluate the safety, tolerability and immunogenicity of a GBS vaccine. Previous studies suggest that immune responses against GBS can protect humans from infection.
- Trial name
- NCT00645346
- Testing
- GBS glycoconjugate vaccine
- Where
- Switzerland
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Infertility
An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)
This study, conducted in India, will be recruiting women participants who are between the ages of 18 and 42, and who have an indication for controlled ovarian stimulation (COS), but have not yet undergone in-vitro fertilization…
- Trial name
- NCT01599494
- Testing
- MK-8962, recFSH, Ganirelix
- Sponsor
- Organon and Co
Endometrial Cancer
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
To assess the objective response rate (ORR: complete response + partial response [CR+ PR]) of E7080 in subjects with unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy. .
- Trial name
- NCT01111461
- Testing
- Lenvatinib
- Where
- 78 sites in United States, Belgium and 6 more
- Volunteers
- 133 people
- Sponsor
- Eisai Inc.
Iron Deficiency
Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age
research study of Ferric carboxymaltose to treat fatigue/exhaustion symptoms, believed to be due to iron deficiency.
- Trial name
- Prefer (NCT01110356)
- Testing
- Ferinject, Saline
- Where
- Austria
- Volunteers
- 294 people
- Sponsor
- Vifor Pharma
Uterine Fibroids, Heavy Menstrual Bleeding
Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids…
- Trial name
- PRIMROSE 2 (NCT03070951)
- Testing
- OBE2109, Add-back
- Where
- 96 sites in United States, Bulgaria and 7 more
- Volunteers
- 511 people
- Sponsor
- ObsEva SA
Renal Impairment
Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment
To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with severe renal impairment and end stage renal disease not on dialysis.
- Trial name
- NCT02852239
- Testing
- dabrafenib
- Where
- 3 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Premature Ejaculation
A Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment of Premature Ejaculation
A phase I, single-center, double-blind, randomized, placebo-controlled, safety and pharmacokinetic study to evaluate systemic and local vaginal exposure to lidocaine and prilocaine and the metabolites, 2,6-dimethylaniline…
- Trial name
- NCT01184105
- Testing
- Intervention A, Intervention B
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Plethora Solutions Ltd
Healthy Volunteers
Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117
The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of escalating single oral doses of AEF0117 in healthy adult male and female subjects.
- Trial name
- NCT03325595
- Testing
- AEF0117
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aelis Farma
Postmenopause
Study Evaluating Premarin and Bazedoxifene Potential Interaction
The purpose of this study is to evaluate the pharmacokinetics (absorption, distribution, breakdown and elimination in the body) of a single dose of bazedoxifene (BZA) 20 mg tablet when administered together with multiple doses of…
- Trial name
- NCT00745173
- Testing
- Premarin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy
Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers
Primary objective:To investigate if BI 10773 affects the pharmacokinetics of ramipril and if ramipril affects the pharmacokinetics of BI 10773.
- Trial name
- NCT01284621
- Testing
- BI 10773, Ramipril
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Solid Tumor
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
The purpose of this study is to assess the potential effects of trabectedin on the QT/QTc interval duration measured by electrocardiograms (ECGs) in participants with advanced solid tumor malignancies when administered at a…
- Trial name
- NCT00786838
- Testing
- Trabectedin
- Where
- 17 sites in United States, Belgium and 5 more
- Volunteers
- 76 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Carcinoma, Renal Cell
RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.
- Conditions
- Carcinoma, Renal Cell, Non Clear Cell Renal Carcinoma, Papillary Cell Renal Carcinoma
- Trial name
- MACS0460 (NCT00688753)
- Testing
- RAD001
- Where
- 19 sites in Belgium, France and 4 more
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Contraception
YAZ, Oral Contraceptive Registration in China
The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive YAZ in healthy Chinese women.
- Trial name
- NCT00819312
- Testing
- YAZ (SH T00186, BAY86-5300)
- Where
- 17 sites in China, Hong Kong
- Volunteers
- 675 people, healthy volunteers welcome
- Sponsor
- Bayer
End Stage Renal Disease (ESRD)
Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine
Randomized, cross-over, controlled, open label study. The aim of this study is to demonstrate that glucose may completely be replaced by a combination of xylitol and carnitine in the bimodal PD solution for long dwell exchange.
- Trial name
- NCT04086212
- Testing
- Icodextrin, xylitol and carnitine solution for peritoneal dialysis, EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution
- Sponsor
- Iperboreal Pharma Srl
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.